Cited by 212Helicobacter pylori-related gastroenterology studiesProbiotics and Fermented FoodsGastrointestinal motility and disorders

Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial

Open access
Nista, E. C., Candelli, M., Cremonini, F., Cazzato, I. A., Zocco, M. A., Franceschi, F., Cammarota, G., Gasbarrini, G. +1 more·2004·Alimentary Pharmacology & Therapeutics

Abstract

Summary: Background : Helicobacter pylori eradication fails in about 10% of patients, particularly because of the occurrence of resistance to antibiotics and side‐effects. During anti‐H. pylori therapy, probiotics have been successfully used to reduce the incidence of side‐effects. Aim : To evaluate the effect of Bacillus clausii, a probiotic, on incidence (primary variable) and severity of antibiotic‐associated side‐effects during anti‐H. pylori therapy. Methods : One hundred and twenty H. pylori‐positive patients were randomly screened to receive: (i) a standard 7 days triple therapy with rabeprazole 20 mg b.d., clarithromycin 500 mg b.d. and amoxicillin 1 g b.d. and B. clausii t.d.s. (each preparation containing 2 × 10 9 spores) for 14 days starting from the first day of treatment. (ii) The same 7 days triple therapy and placebo t.d.s. for 14 days starting from the first day of treatment. Side‐effects were assessed using a validated questionnaire and were recorded for 4 weeks from the start of therapy. Results : The incidences of nausea, diarrhoea and epigastric pain in patients treated with B. clausii were significantly lower than in placebo group, in both PP and ITT analysis. Equally, intensity of nausea and diarrhoea in patients treated with B. clausii was significantly lower than in placebo group. There were no differences in adherence to treatment and H. pylori eradication rates between groups. Conclusion : In symptom‐free, H. pylori‐positive subjects B. clausii bacteriotherapy reduces the incidence of the most common side‐effects related to anti‐H. pylori antibiotic therapy compared with placebo.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2036.2004.02274.x

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Ciffo F, Da Carro C, Giovannetti M. Gastric resistance of Bacillus subtilis spores used in oral bacteriotherapy: in vitro studies. Farmaci e terapia 1987; 3: 163-169.

Cited by

Sorted by citations

Authors
Nista, E. C., Candelli, M., Cremonini, F., Cazzato, I. A., Zocco, M. A., Franceschi, F., Cammarota, G., Gasbarrini, G., & Gasbarrini, A.
Affiliations
Università Cattolica del Sacro Cuore (IT)
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2004-11
Volume
20
Issue
10
Pages
1181-1188
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W2120773585
Cited by
212
References
27
Citations by year
2026: 4 · 2025: 2 · 2024: 12 · 2023: 15 · 2022: 29 · 2021: 8 · 2020: 6 · 2019: 7 · 2018: 2 · 2017: 9 · 2016: 11 · 2015: 9 · 2014: 8 · 2013: 16 · 2012: 11
FWCI
11.37
Type
journal article
Language
en
Open access
Locations
  • Alimentary Pharmacology & Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Helicobacter pylori-related gastroenterology studies
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
Keywords
Bacillus clausii, probiotics, Helicobacter pylori eradication, antibiotic adverse effects, triple therapy, clarithromycin, amoxicillin, rabeprazole, nausea, diarrhea, epigastric pain, Helicobacter pylori infection
MeSH terms
Adolescent, Adult, Aged, Amoxicillin, Anti-Ulcer Agents, Bacillus, Benzimidazoles, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Omeprazole, Prospective Studies, Helicobacter pylori, Helicobacter Infections, Clarithromycin, Probiotics, 2-Pyridinylmethylsulfinylbenzimidazoles, Rabeprazole

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review